Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
ApexOnco Front Page
Recent articles
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
